Walleye Capital LLC Takes Position in Vapotherm, Inc. (NYSE:VAPO)

Walleye Capital LLC acquired a new stake in shares of Vapotherm, Inc. (NYSE:VAPOGet Rating) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 149,800 shares of the company’s stock, valued at approximately $379,000. Walleye Capital LLC owned 0.56% of Vapotherm as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in VAPO. Private Advisor Group LLC purchased a new stake in Vapotherm during the 2nd quarter worth $38,000. Sawtooth Solutions LLC purchased a new stake in Vapotherm during the 2nd quarter worth $38,000. Mayflower Financial Advisors LLC boosted its position in Vapotherm by 51.2% during the 2nd quarter. Mayflower Financial Advisors LLC now owns 16,400 shares of the company’s stock worth $41,000 after purchasing an additional 5,550 shares during the period. Cambridge Investment Research Advisors Inc. boosted its position in Vapotherm by 28.9% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 45,558 shares of the company’s stock worth $115,000 after purchasing an additional 10,208 shares during the period. Finally, MetLife Investment Management LLC boosted its position in Vapotherm by 60.7% during the 1st quarter. MetLife Investment Management LLC now owns 14,161 shares of the company’s stock worth $197,000 after purchasing an additional 5,351 shares during the period. 54.04% of the stock is owned by hedge funds and other institutional investors.

Vapotherm Stock Down 10.5 %

NYSE:VAPO opened at $0.49 on Thursday. The company has a debt-to-equity ratio of 7.04, a current ratio of 3.88 and a quick ratio of 2.03. The firm has a 50-day moving average of $1.45 and a two-hundred day moving average of $2.19. Vapotherm, Inc. has a 1-year low of $0.49 and a 1-year high of $24.23.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. BTIG Research cut shares of Vapotherm from a “buy” rating to a “neutral” rating in a research report on Thursday, August 4th. Piper Sandler decreased their price target on shares of Vapotherm from $2.50 to $2.00 and set an “underweight” rating for the company in a research report on Thursday, August 4th. Finally, William Blair cut shares of Vapotherm from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 4th. One investment analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. According to MarketBeat, Vapotherm has an average rating of “Hold” and an average target price of $4.75.

Vapotherm Profile

(Get Rating)

Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.

See Also

Institutional Ownership by Quarter for Vapotherm (NYSE:VAPO)

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.